Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mirati Therapeutics (NQ: MRTX ) N/A UNCHANGED Last Price Updated: 4:00 PM EST, Jan 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Mirati Therapeutics Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment November 29, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Exposures Death MIRATI THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX November 08, 2023 From Kahn Swick & Foti, LLC Via Business Wire Bristol Myers Squibb Enters the Multi-Billion-Dollar Oncology Race October 17, 2023 Major pharmaceutical companies are continuing to make substantial acquisitions in the field of oncology, sparking enthusiasm in the market. Bristol Myers Squibb (NYSE:BMY) just announced its plan to... Via PressReach Mirati Therapeutics, Inc. (NASDAQ:MRTX) Investor Alert: Investigation over Possible Breaches of Fiduciary Duties May 11, 2023 San Diego, CA -- (SBWIRE) -- 05/11/2023 -- Certain directors of Mirati Therapeutics, Inc are under investigation over potential breaches of fiduciary duties. Via SBWire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Consolidated Communications Holdings, Inc. (Nasdaq – CNSL), Mirati Therapeutics, Inc.® (Nasdaq - MRTX), Pioneer Natural Resources (NYSE - PXD), Summit Materials (NYSE October 16, 2023 From Brodsky & Smith LLC Via GlobeNewswire Elli Lilly Joins Big Pharma’s Multi-Billion-Dollar Oncology Race October 10, 2023 Large pharmaceutical companies are increasingly investing in cancer treatment stocks, driven by the promise of medical breakthroughs and financial rewards. Eli Lilly became the latest Big Pharma giant... Via PressReach MIRATI THERAPEUTICS INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mirati Therapeutics, Inc. - MRTX October 09, 2023 From Kahn Swick & Foti, LLC Via Business Wire BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Mirati Therapeutics, Inc.® (Nasdaq - MRTX), LiveVox Holdings, Inc. (Nasdaq - LVOX), SP® Plus Corporation (Nasdaq - SP), Summit Materials (NYSE - SUM) October 09, 2023 From Brodsky & Smith LLC Via GlobeNewswire MRTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Mirati Therapeutics, Inc. Is Fair to Shareholders October 08, 2023 From Halper Sadeh LLC Via Business Wire Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics October 08, 2023 From Bristol Myers Squibb Via Business Wire Pancreatic Cancer Battle Boosted by $200M VC Firm September 19, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:MACK),(NASDAQ:INCY),(NASDAQ:MRTX),(NASDAQ:BNTX) EQNX::TICKER_END Via FinancialNewsMedia Topics Death Exposures Death Increased Funding for Pancreatic Cancer Trials & Treatments Rising along with Demand for New Drugs June 22, 2023 EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:POAI),(NASDAQ:AGLE),(NASDAQ:TALS),(NASDAQ:MRTX) EQNX::TICKER_END Via FinancialNewsMedia Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer November 15, 2022 FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 15, 2022 – USA News Group – Roughly five years after selling its flagship cancer asset Onivyde from to French biotech... Via FinancialNewsMedia Topics Death Exposures Death Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors November 07, 2022 From Incyte and Mirati Via Business Wire INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Mirati Therapeutics, Inc. with Losses of $100,000 to Contact the Firm June 16, 2022 From The Schall Law Firm Via Business Wire Artificial Intelligence Being Used to Accurately Predict Synergistic Cancer Drug Combinations December 10, 2021 FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 10, 2021 – USA News Group – Researchers led by a scholar from City University of Hong Kong (CityU) have developed a novel... Via FinancialNewsMedia Topics Artificial Intelligence Exposures Artificial Intelligence Investigation Announced for Long-Term Investors in Mirati Therapeutics, Inc. (NASDAQ:MRTX) December 07, 2021 San Diego, CA -- (SBWIRE) -- 12/07/2021 -- Certain directors of Mirati Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Via SBWire Topics Regulatory Compliance Exposures Legal Regulatory Mirati Therapeutics and Verastem Oncology Partner to Evaluate Adagrasib in Combination with VS-6766 in KRASG12C-Mutant Non-Small Cell Lung Cancer November 22, 2021 From Verastem Oncology Via Business Wire NASDAQ:MRTX Investor Notice: Investigation over Possible Securities Laws Violations by Mirati Therapeutics, Inc. November 08, 2021 San Diego, CA -- (SBWIRE) -- 11/08/2021 -- Mirati Therapeutics, Inc. is under investigation over potential securities laws violations in connection with certain financial statements. Via SBWire Topics Regulatory Compliance Exposures Legal Regulatory QIAGEN Partners With Mirati Therapeutics Inc. to Develop KRASG12C Companion Diagnostic for Non-Small Cell Lung Cancer (NSCLC) May 25, 2021 From QIAGEN N.V. Via Business Wire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.